Cantor Fitzgerald analyst Charles Duncan downgraded Reata Pharmaceuticals (RETA) to Neutral from Overweight after Biogen (BIIB) agreed to acquire Reata for $172.50 per share in cash.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RETA: